News

Press release

Financial Press Release | Oncodesign
Press release
05/01/2016

Oncodesign Biotechnology and Bristol-Myers Squibb enter into Strategic Drug Discovery Collaboration

Read more
Financial Press Release | Oncodesign
Press release
17/12/2015

Preclinical validation of Oncodesign’s first radiotracer prior to human application

Read more
Financial Press Release | Oncodesign
Press release
21/10/2015

Oncodesign presents novel LRRK2 inhibitor jointly discovered with Ipsen at the 2015 Neurosciences meeting in Chicago

Read more
Financial Press Release | Oncodesign
Press release
16/10/2015

Oncodesign pursues its strategy of expansion in North America

Read more
Financial Press Release | Oncodesign
Press release
16/07/2015

Oncodesign announces the creation of its Scientific Advisory Board

Read more
Financial Press Release | Oncodesign
Press release
02/06/2015

UCB exercises its option to license a program from Oncodesign targeting neurological diseases

Read more
Financial Press Release | Oncodesign
Press release
28/04/2015

Oncodesign presents new supportive data for its Nanocyclix based RIPK2 program for auto-immune disease at the 10th Drug Discovery Chemistry conference in San Diego, CA

Read more
Financial Press Release | Oncodesign
Press release
26/03/2015

Oncodesign signs additional 2-year preclinical research contract to evaluate antibody-drug conjugates

Read more
Financial Press Release | Oncodesign
Press release
17/12/2014

Europe – Oncodesign has entered into a services agreement with Eisai to develop a new personalized medicine program in earlier line metastatic breast cancer treatment

Read more
Financial Press Release | Oncodesign
Press release
04/11/2014

Oncodesign announces the third extension of a research contract with Isarna Therapeutics

Read more
Financial Press Release | Oncodesign
Press release
13/10/2014

Oncodesign seals a major research agreement with Cellectis

Read more
Financial Press Release | Oncodesign
Press release
29/09/2014

Oncodesign announces the discovery of new molecule inhibitors of inflammatory disease and the publication of 3 new patent applications

Read more